home / stock / sbtx / sbtx quote
Last: | $5.87 |
---|---|
Change Percent: | -0.17% |
Open: | $5.82 |
Close: | $5.87 |
High: | $6.15 |
Low: | $5.72 |
Volume: | 116,700 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.87 | $5.82 | $5.87 | $6.15 | $5.72 | 116,700 | 11-08-2022 |
$5.81 | $6.05 | $5.81 | $6.135 | $5.8 | 158,815 | 11-07-2022 |
$6.01 | $6.1 | $6.01 | $6.1 | $5.86 | 130,885 | 11-04-2022 |
$6.06 | $6.2 | $6.06 | $6.41 | $6.05 | 94,203 | 11-03-2022 |
$6.23 | $6.16 | $6.23 | $6.46 | $5.89 | 140,774 | 11-02-2022 |
$6.15 | $6.27 | $6.15 | $6.32 | $6.13 | 47,771 | 11-01-2022 |
$6.22 | $6.14 | $6.22 | $6.5 | $6.08 | 372,532 | 10-31-2022 |
$6.14 | $5.82 | $6.14 | $6.15 | $5.63 | 206,823 | 10-28-2022 |
$5.78 | $6.18 | $5.78 | $6.18 | $5.545 | 230,517 | 10-27-2022 |
$6.14 | $6.12 | $6.14 | $6.4 | $6.08 | 290,154 | 10-26-2022 |
$6.13 | $5.84 | $6.13 | $6.4 | $5.84 | 306,580 | 10-25-2022 |
$5.83 | $5.75 | $5.83 | $5.97 | $5.51 | 198,243 | 10-24-2022 |
$5.73 | $6.02 | $5.73 | $6.0299 | $5.45 | 187,348 | 10-21-2022 |
$5.9 | $5.79 | $5.9 | $6.1201 | $5.75 | 595,079 | 10-20-2022 |
$5.26 | $5.59 | $5.26 | $5.62 | $5.2 | 51,285 | 10-19-2022 |
$5.62 | $5.35 | $5.62 | $5.73 | $5.35 | 456,062 | 10-18-2022 |
$5.5 | $5.26 | $5.5 | $5.58 | $5.26 | 159,770 | 10-17-2022 |
$5.24 | $5.11 | $5.24 | $5.24 | $5.04 | 55,583 | 10-14-2022 |
$5.17 | $4.97 | $5.17 | $5.17 | $4.91 | 58,500 | 10-13-2022 |
$5.03 | $5.24 | $5.03 | $5.245 | $4.96 | 48,941 | 10-12-2022 |
News, Short Squeeze, Breakout and More Instantly...
Silverback Therapeutics Inc. Company Name:
SBTX Stock Symbol:
NASDAQ Market:
Preparing to submit response to the FDA’s CRL for neffy ® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with ...
Significant unmet need with 80-90% of patients with current epinephrine Rx not using as directed, and only ~15% of diagnosed severe Type I allergy population with a current epinephrine prescription Multiple favorable attributes and potential best-in-class profile of neffy highlighted ...
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participa...